The results of multicenter, randomized, double-blind comparative study of linezolid and vancomycin efficacy, safety and tolerability in the treatment of nosocomial pneumonia are presented. The trial was performed on 69 patients. Clinical efficacy of linezolid was 83 per cent, of vancomycin--79 per cent. Bacteriological effect (pathogen eradication) was 83 per cent for linezolid group and 86 per cent for vancomycin group. During the study good clinical tolerability of linezolid was demonstrated along with lower side effects incidence and shortened recovery period when compared to vancomycin.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Microbiological Spectrum and Antibiotics Sensitivity Pattern of Chronic Suppurative Otitis Media (CSOM) Patients: A prospective study from a Tertiary Care Hospital in Peshawar.
Pak J Med Sci
January 2025
Inzimam Ul Haq Postgraduate trainee, Department of ENT, MTI Khyber Teaching Hospital, University Road Peshawar, Pakistan.
Background & Objective: Chronic suppurative otitis media is a fatal condition owing to its propensity for intracranial extension. The inadvertent use of antibiotics has led to resistance among causative organisms. The objectives of this study were to determine causative bacteria, their antibiotic resistance and susceptibility patterns, and their response to antibiotics after a one-month follow-up.
View Article and Find Full Text PDFBenchmarking antimicrobial use to antimicrobial resistance: a comparative study of two hospitals using current National Healthcare Safety Network (NHSN) metrics.
Infect Control Hosp Epidemiol
January 2025
Center for Health Equity and Innovation, Cook County Health, Chicago, IL, USA.
Objective: We aimed to determine whether benchmarking antimicrobial use (AU) to antimicrobial resistance (AR) using select AU/AR ratios is more informative than AU metrics in isolation.
Design: We retrospectively measured AU (antimicrobial therapy days per 1,000 days present) and AU/AR ratios (specific antimicrobial therapy days per corresponding AR event) in two hospitals during 2020 through 2022. We then had antimicrobial stewardship committee members evaluate each AU and corresponding AU/AR value and indicate whether they believed it represented potential overuse, appropriate use, or potential underuse of the antimicrobials, or whether they could not provide an assessment.
Therapeutic Drug Monitoring-Guided Linezolid Therapy for the Treatment of Multiple Staphylococcal Brain Abscesses in a 3-Month-Old Infant.
Pathogens
December 2024
Infectious Disease Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Brain abscesses are invasive infections of the central nervous system with a high level of treatment complexity especially in pediatric patients. Here, we describe a 3-month-old infant with multiple brain abscesses caused by methicillin-susceptible (MSSA). The patient was initially treated with empirical antibiotics (ceftriaxone, metronidazole, vancomycin).
View Article and Find Full Text PDFThe Changes in the Antibiotic Resistance of , , and in the Clinical Isolates of a Multiprofile Hospital over 6 Years (2017-2022).
J Clin Med
January 2025
Department of Medical Biology, Faculty of Nursing and Midwifery, Wroclaw Medical University, 50-368 Wroclaw, Poland.
The growing resistance of bacteria to antibiotics is a serious problem in health care. The present study aims to assess the drug resistance of , , and isolated from infections in a multispecialty hospital over a 6-year period. Identification and antimicrobial susceptibility testing were performed using the VITEK2 automated system (Biomerieux).
View Article and Find Full Text PDFFirst Detection and Genomic Characterization of Linezolid-Resistant Clinical Isolates in Bulgaria.
Microorganisms
January 2025
Department of Medical Microbiology "Corr. Mem. Prof. Ivan Mitov, MD, DMSc", Faculty of Medicine, Medical University of Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria.
Linezolid is an oxazolidinone antibiotic and is considered a last-resort treatment option for serious infections caused by problematic Gram-positive pathogens, including vancomycin-resistant enterococci. The present study aimed to explore the linezolid resistance mechanisms and genomic characteristics of two vancomycin-susceptible isolates from Bulgaria. The strains designated Efs2503-bg (inpatient from Pleven) and Efs966-bg (outpatient from Varna) were recovered from wounds in 2018 and 2023, respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!